Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 69

1.

Preexposure Prophylaxis for Mitigating Risk of HIV Transmission During HIV Cure-Related Clinical Trials With a Treatment Interruption.

Lelièvre JD.

J Infect Dis. 2019 Mar 12. pii: jiz036. doi: 10.1093/infdis/jiz036. [Epub ahead of print]

PMID:
30860581
2.

HIV controllers have low inflammation associated with a strong HIV-specific immune response in blood.

Hocini H, Bonnabau H, Lacabaratz C, Lefebvre C, Tisserand P, Foucat E, Lelièvre JD, Lambotte O, Saez-Cirion A, Versmisse P, Thiébaut R, Lévy Y.

J Virol. 2019 Feb 27. pii: JVI.01690-18. doi: 10.1128/JVI.01690-18. [Epub ahead of print]

PMID:
30814287
3.

Unintended HIV-1 Transmission to a Sex Partner in a Study of a Therapeutic Vaccine Candidate.

Lelièvre JD, Hocqueloux L.

J Infect Dis. 2019 Feb 16. pii: jiz012. doi: 10.1093/infdis/jiz012. [Epub ahead of print]

PMID:
30779842
4.

Low incidence of acute rejection within 6 months of kidney transplantation in HIV-infected recipients treated with raltegravir: the Agence Nationale de Recherche sur le Sida et les Hépatites Virales (ANRS) 153 TREVE trial.

Matignon M, Lelièvre JD, Lahiani A, Abbassi K, Desvaux D, Diallo A, Peraldi MN, Taburet AM, Saillard J, Delaugerre C, Costagliola D, Assoumou L, Grimbert P; ANRS 153 TREVE study group.

HIV Med. 2019 Mar;20(3):202-213. doi: 10.1111/hiv.12700. Epub 2019 Jan 27.

PMID:
30688008
5.

Safety of elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in HIV-1-infected adults with end-stage renal disease on chronic haemodialysis: an open-label, single-arm, multicentre, phase 3b trial.

Eron JJ Jr, Lelievre JD, Kalayjian R, Slim J, Wurapa AK, Stephens JL, McDonald C, Cua E, Wilkin A, Schmied B, McKellar M, Cox S, Majeed SR, Jiang S, Cheng A, Das M, SenGupta D.

Lancet HIV. 2018 Dec 13. pii: S2352-3018(18)30296-0. doi: 10.1016/S2352-3018(18)30296-0. [Epub ahead of print]

PMID:
30555051
6.

Viral rebound in semen after antiretroviral treatment interruption in an HIV therapeutic vaccine double-blind trial.

Palich R, Ghosn J, Chaillon A, Boilet V, Nere ML, Chaix ML, Delobel P, Molina JM, Lucht F, Bouchaud O, Rieux V, Thiebaut R, Levy Y, Delaugerre C, Lelievre JD; VRI02/ANRS149 LIGHT Vaccine Trial Group.

AIDS. 2019 Feb 1;33(2):279-284. doi: 10.1097/QAD.0000000000002058.

PMID:
30325777
7.

Interview With Jean-Daniel Lelièvre, PU-PH, Head of the Research Clinic of the VRI (Vaccine Research Institute).

Lelievre JD, Ollivier-Yaniv C.

J Acquir Immune Defic Syndr. 2018 Oct 1;79 Suppl 1:S8-S12. doi: 10.1097/QAI.0000000000001813. No abstract available.

PMID:
30222700
8.

Progress towards obtaining an HIV cure: slow but sure.

Henrich TJ, Lelièvre JD.

Curr Opin HIV AIDS. 2018 Sep;13(5):381-382. doi: 10.1097/COH.0000000000000492. No abstract available.

PMID:
29965799
9.

Early Antiretroviral Therapy Preserves Functional Follicular Helper T and HIV-Specific B Cells in the Gut Mucosa of HIV-1-Infected Individuals.

Planchais C, Hocqueloux L, Ibanez C, Gallien S, Copie C, Surenaud M, Kök A, Lorin V, Fusaro M, Delfau-Larue MH, Lefrou L, Prazuck T, Lévy M, Seddiki N, Lelièvre JD, Mouquet H, Lévy Y, Hüe S.

J Immunol. 2018 May 15;200(10):3519-3529. doi: 10.4049/jimmunol.1701615. Epub 2018 Apr 9.

PMID:
29632141
10.

Acceptability of HIV cure-related trials: the challenges for physicians and people living with HIV (ANRS-APSEC).

Preau M, Doumergue M, Protiere C, Goujard C, Mora M, Meyer L, Lelievre JD, Raffi F, Spire B, Lambotte O, Suzan-Monti M.

AIDS Care. 2018 Jul;30(7):914-920. doi: 10.1080/09540121.2018.1426825. Epub 2018 Jan 18.

PMID:
29347826
11.

Hospitalization of HIV positive patients: Significant demand affecting all hospital sectors.

Seng R, Mutuon P, Riou J, Duvivier C, Weiss L, Lelievre JD, Meyer L, Vittecoq D, Zak Dit Zbar O, Frenkiel J, Frank-Soltysiak M, Boue F, Rapp C, Sobel A, Brucker G, Goujard C, Salmon D; COREVIH.

Rev Epidemiol Sante Publique. 2018 Feb;66(1):7-17. doi: 10.1016/j.respe.2017.08.002. Epub 2017 Dec 10.

PMID:
29233572
12.

Serum suppression of tumorigenicity 2 level is an independent predictor of all-cause mortality in HIV-infected patients.

Thiébaut R, Hue S, Le Marec F, Lelièvre JD, Dupon M, Foucat E, Lazaro E, Dabis F, Duffau P, Wittkop L, Surenaud M, Pellegrin I, Lacabaratz C, Bonnet F, Lévy Y; ANRS CO3 Aquitaine Cohort.

AIDS. 2017 Nov 13;31(17):2355-2365. doi: 10.1097/QAD.0000000000001628.

PMID:
29068834
13.

Incidence and predictive score for delayed hemolytic transfusion reaction in adult patients with sickle cell disease.

Narbey D, Habibi A, Chadebech P, Mekontso-Dessap A, Khellaf M, Lelièvre JD, Godeau B, Michel M, Galactéros F, Djoudi R, Bartolucci P, Pirenne F.

Am J Hematol. 2017 Dec;92(12):1340-1348. doi: 10.1002/ajh.24908. Epub 2017 Oct 31.

14.

Impaired humoral and cellular immune responses to influenza vaccination in chronic obstructive pulmonary disease patients.

Parpaleix A, Boyer L, Wiedemann A, Lacabaratz C, Margarit L, Enouf V, Le Corvoisier P, Lino A, Covali-Noroc A, Housset B, Chouaid C, Maitre B, Lévy Y, Lelièvre JD, Adnot S.

J Allergy Clin Immunol. 2017 Dec;140(6):1754-1757.e6. doi: 10.1016/j.jaci.2017.07.038. Epub 2017 Sep 7. No abstract available.

PMID:
28889955
15.

Development of an epitope-based HIV-1 vaccine strategy from HIV-1 lipopeptide to dendritic-based vaccines.

Surenaud M, Lacabaratz C, Zurawski G, Lévy Y, Lelièvre JD.

Expert Rev Vaccines. 2017 Oct;16(10):955-972. doi: 10.1080/14760584.2017.1374182. Review.

PMID:
28879788
16.

Negative modulation of suppressive HIV-specific regulatory T cells by IL-2 adjuvanted therapeutic vaccine.

Brezar V, Hani L, Surenaud M, Hubert A, Lacabaratz C, Lelièvre JD, Levy Y, Seddiki N.

PLoS Pathog. 2017 Jul 14;13(7):e1006489. doi: 10.1371/journal.ppat.1006489. eCollection 2017 Jul.

17.

CD32a is a marker of a CD4 T-cell HIV reservoir harbouring replication-competent proviruses.

Descours B, Petitjean G, López-Zaragoza JL, Bruel T, Raffel R, Psomas C, Reynes J, Lacabaratz C, Levy Y, Schwartz O, Lelievre JD, Benkirane M.

Nature. 2017 Mar 23;543(7646):564-567. doi: 10.1038/nature21710. Epub 2017 Mar 15. Erratum in: Nature. 2017 Jun 28;546(7660):686.

PMID:
28297712
18.

Successful improvement of Buschke-Löwenstein tumour in an HIV-infected patient with antiretroviral therapy alone.

Grodner C, Henn A, Lelièvre JD, Gallien S.

BMJ Case Rep. 2016 Nov 21;2016. pii: bcr2016217753. doi: 10.1136/bcr-2016-217753.

19.

HIV-1 prophylactic vaccines: state of the art.

Lelièvre JD, Lévy Y.

J Virus Erad. 2016 Jan 1;2(1):5-11. Review.

20.

P2X7 Receptor Inhibition Improves CD34 T-Cell Differentiation in HIV-Infected Immunological Nonresponders on c-ART.

Menkova-Garnier I, Hocini H, Foucat E, Tisserand P, Bourdery L, Delaugerre C, Benne C, Lévy Y, Lelièvre JD.

PLoS Pathog. 2016 Apr 15;12(4):e1005571. doi: 10.1371/journal.ppat.1005571. eCollection 2016 Apr.

21.

The F4/AS01B HIV-1 Vaccine Candidate Is Safe and Immunogenic, But Does Not Show Viral Efficacy in Antiretroviral Therapy-Naive, HIV-1-Infected Adults: A Randomized Controlled Trial.

Dinges W, Girard PM, Podzamczer D, Brockmeyer NH, García F, Harrer T, Lelievre JD, Frank I, Colin De Verdière N, Yeni GP, Ortega Gonzalez E, Rubio R, Clotet Sala B, DeJesus E, Pérez-Elias MJ, Launay O, Pialoux G, Slim J, Weiss L, Bouchaud O, Felizarta F, Meurer A, Raffi F, Esser S, Katlama C, Koletar SL, Mounzer K, Swindells S, Baxter JD, Schneider S, Chas J, Molina JM, Koutsoukos M, Collard A, Bourguignon P, Roman F.

Medicine (Baltimore). 2016 Feb;95(6):e2673. doi: 10.1097/MD.0000000000002673.

22.

Spectrum of adult Parvovirus B19 infection according to the underlying predisposing condition and proposals for clinical practice.

Wolfromm A, Rodriguez C, Michel M, Habibi A, Audard V, Benayoun E, Rogier O, Challine D, Chosidow O, Lelièvre JD, Chevalier X, Le Bras F, Pautas C, Imbert M, Pawlotsky JM, Wagner-Ballon O.

Br J Haematol. 2015 Jul;170(2):192-9. doi: 10.1111/bjh.13421. Epub 2015 Apr 28.

PMID:
25920561
23.

Low SAMHD1 expression following T-cell activation and proliferation renders CD4+ T cells susceptible to HIV-1.

Ruffin N, Brezar V, Ayinde D, Lefebvre C, Schulze Zur Wiesch J, van Lunzen J, Bockhorn M, Schwartz O, Hocini H, Lelievre JD, Banchereau J, Levy Y, Seddiki N.

AIDS. 2015 Mar 13;29(5):519-30. doi: 10.1097/QAD.0000000000000594.

24.

[Lines of research in the treatment of HIV infection].

Saidani M, Lelièvre JD.

Rev Prat. 2014 Oct;64(8):1103-6. French.

PMID:
25510135
25.

Accelerating clinical development of HIV vaccine strategies: methodological challenges and considerations in constructing an optimised multi-arm phase I/II trial design.

Richert L, Doussau A, Lelièvre JD, Arnold V, Rieux V, Bouakane A, Lévy Y, Chêne G, Thiébaut R; Vaccine Research Institute (VRI).

Trials. 2014 Feb 26;15:68. doi: 10.1186/1745-6215-15-68.

26.

HIV "elite controllers" are characterized by a high frequency of memory CD8+ CD73+ T cells involved in the antigen-specific CD8+ T-cell response.

Carrière M, Lacabaratz C, Kök A, Benne C, Jenabian MA, Casartelli N, Hüe S, Hocqueloux L, Lelièvre JD, Lévy Y.

J Infect Dis. 2014 May 1;209(9):1321-30. doi: 10.1093/infdis/jit643. Epub 2013 Dec 19.

PMID:
24357632
27.

The capsids of HIV-1 and HIV-2 determine immune detection of the viral cDNA by the innate sensor cGAS in dendritic cells.

Lahaye X, Satoh T, Gentili M, Cerboni S, Conrad C, Hurbain I, El Marjou A, Lacabaratz C, Lelièvre JD, Manel N.

Immunity. 2013 Dec 12;39(6):1132-42. doi: 10.1016/j.immuni.2013.11.002. Epub 2013 Nov 21.

28.

IL-7 modulates in vitro and in vivo human memory T regulatory cell functions through the CD39/ATP axis.

Younas M, Hue S, Lacabaratz C, Guguin A, Wiedemann A, Surenaud M, Beq S, Croughs T, Lelièvre JD, Lévy Y.

J Immunol. 2013 Sep 15;191(6):3161-8. doi: 10.4049/jimmunol.1203547. Epub 2013 Aug 21.

29.

Cytokine and gene transcription profiles of immune responses elicited by HIV lipopeptide vaccine in HIV-negative volunteers.

Richert L, Hue S, Hocini H, Raimbault M, Lacabaratz C, Surenaud M, Wiedemann A, Tisserand P, Durier C, Salmon D, Lelièvre JD, Chêne G, Thiébaut R, Lévy Y; ANRS Vaccine Network/Vaccine Research Institute.

AIDS. 2013 Jun 1;27(9):1421-31. doi: 10.1097/QAD.0b013e32835f5b60.

PMID:
23759749
30.

Regulatory T cells negatively affect IL-2 production of effector T cells through CD39/adenosine pathway in HIV infection.

Jenabian MA, Seddiki N, Yatim A, Carriere M, Hulin A, Younas M, Ghadimi E, Kök A, Routy JP, Tremblay A, Sévigny J, Lelievre JD, Levy Y.

PLoS Pathog. 2013;9(4):e1003319. doi: 10.1371/journal.ppat.1003319. Epub 2013 Apr 25.

31.

NOTCH1 nuclear interactome reveals key regulators of its transcriptional activity and oncogenic function.

Yatim A, Benne C, Sobhian B, Laurent-Chabalier S, Deas O, Judde JG, Lelievre JD, Levy Y, Benkirane M.

Mol Cell. 2012 Nov 9;48(3):445-58. doi: 10.1016/j.molcel.2012.08.022. Epub 2012 Sep 27.

32.

Initiation of c-ART in HIV-1 infected patients is associated with a decrease of the metabolic activity of the thymus evaluated using FDG-PET/computed tomography.

Lelièvre JD, Melica G, Itti E, Lacabaratz C, Rozlan S, Wiedemann A, Cheynier R, Meignan M, Thiebaut R, Levy Y.

J Acquir Immune Defic Syndr. 2012 Sep 1;61(1):56-63. doi: 10.1097/QAI.0b013e3182615b62.

PMID:
22706292
33.

Effects of recombinant human interleukin 7 on T-cell recovery and thymic output in HIV-infected patients receiving antiretroviral therapy: results of a phase I/IIa randomized, placebo-controlled, multicenter study.

Lévy Y, Sereti I, Tambussi G, Routy JP, Lelièvre JD, Delfraissy JF, Molina JM, Fischl M, Goujard C, Rodriguez B, Rouzioux C, Avettand-Fenoël V, Croughs T, Beq S, Morre M, Poulin JF, Sekaly RP, Thiebaut R, Lederman MM.

Clin Infect Dis. 2012 Jul;55(2):291-300. doi: 10.1093/cid/cis383. Epub 2012 May 1.

34.

Altered thymic function during interferon therapy in HCV-infected patients.

Beq S, Rozlan S, Pelletier S, Willems B, Bruneau J, Lelievre JD, Levy Y, Shoukry NH, Cheynier R.

PLoS One. 2012;7(4):e34326. doi: 10.1371/journal.pone.0034326. Epub 2012 Apr 16.

35.

Identification of IL7RA risk alleles for rapid progression during HIV-1 infection: a comprehensive study in the GRIV cohort.

Limou S, Melica G, Coulonges C, Lelièvre JD, Do H, McGinn S, Gut IG, Lévy Y, Zagury JF.

Curr HIV Res. 2012 Mar;10(2):143-50.

PMID:
22329520
36.

CD39/adenosine pathway is involved in AIDS progression.

Nikolova M, Carriere M, Jenabian MA, Limou S, Younas M, Kök A, Huë S, Seddiki N, Hulin A, Delaneau O, Schuitemaker H, Herbeck JT, Mullins JI, Muhtarova M, Bensussan A, Zagury JF, Lelievre JD, Lévy Y.

PLoS Pathog. 2011 Jul;7(7):e1002110. doi: 10.1371/journal.ppat.1002110. Epub 2011 Jul 7.

37.

Multiple-cohort genetic association study reveals CXCR6 as a new chemokine receptor involved in long-term nonprogression to AIDS.

Limou S, Coulonges C, Herbeck JT, van Manen D, An P, Le Clerc S, Delaneau O, Diop G, Taing L, Montes M, van't Wout AB, Gottlieb GS, Therwath A, Rouzioux C, Delfraissy JF, Lelièvre JD, Lévy Y, Hercberg S, Dina C, Phair J, Donfield S, Goedert JJ, Buchbinder S, Estaquier J, Schächter F, Gut I, Froguel P, Mullins JI, Schuitemaker H, Winkler C, Zagury JF.

J Infect Dis. 2010 Sep 15;202(6):908-15. doi: 10.1086/655782.

38.

Immunogenicity and safety of an HIV-1 lipopeptide vaccine in healthy adults: a phase 2 placebo-controlled ANRS trial.

Salmon-Céron D, Durier C, Desaint C, Cuzin L, Surenaud M, Hamouda NB, Lelièvre JD, Bonnet B, Pialoux G, Poizot-Martin I, Aboulker JP, Lévy Y, Launay O; ANRS VAC18 trial group.

AIDS. 2010 Sep 10;24(14):2211-23. doi: 10.1097/QAD.0b013e32833ce566.

PMID:
20625264
39.

Maraviroc-containing regimen suppresses HIV replication in the cerebrospinal fluid of patients with neurological symptoms.

Melica G, Canestri A, Peytavin G, Lelievre JD, Bouvier-Alias M, Clavel C, Calvez V, Lascaux AS, Katlama C, Levy Y.

AIDS. 2010 Aug 24;24(13):2130-3. doi: 10.1097/QAD.0b013e32833c9353.

PMID:
20601852
40.

Cutaneous macroglobulinosis: a report of 2 cases.

Gressier L, Hotz C, Lelièvre JD, Carlotti A, Buffet M, Wolkenstein P, Bagot M, Melica G, Ortonne N.

Arch Dermatol. 2010 Feb;146(2):165-9. doi: 10.1001/archdermatol.2009.359.

PMID:
20157027
41.

Genomewide association study of a rapid progression cohort identifies new susceptibility alleles for AIDS (ANRS Genomewide Association Study 03).

Le Clerc S, Limou S, Coulonges C, Carpentier W, Dina C, Taing L, Delaneau O, Labib T, Sladek R; ANRS Genomic Group, Deveau C, Guillemain H, Ratsimandresy R, Montes M, Spadoni JL, Therwath A, Schächter F, Matsuda F, Gut I, Lelièvre JD, Lévy Y, Froguel P, Delfraissy JF, Hercberg S, Zagury JF.

J Infect Dis. 2009 Oct 15;200(8):1194-201. doi: 10.1086/605892.

PMID:
19754311
42.

Notch increases T/NK potential of human hematopoietic progenitors and inhibits B cell differentiation at a pro-B stage.

Benne C, Lelievre JD, Balbo M, Henry A, Sakano S, Levy Y.

Stem Cells. 2009 Jul;27(7):1676-85. doi: 10.1002/stem.94.

43.

Notch ligands potentiate IL-7-driven proliferation and survival of human thymocyte precursors.

Magri M, Yatim A, Benne C, Balbo M, Henry A, Serraf A, Sakano S, Gazzolo L, Lévy Y, Lelièvre JD.

Eur J Immunol. 2009 May;39(5):1231-40. doi: 10.1002/eji.200838765.

44.

Enhanced T cell recovery in HIV-1-infected adults through IL-7 treatment.

Levy Y, Lacabaratz C, Weiss L, Viard JP, Goujard C, Lelièvre JD, Boué F, Molina JM, Rouzioux C, Avettand-Fénoêl V, Croughs T, Beq S, Thiébaut R, Chêne G, Morre M, Delfraissy JF.

J Clin Invest. 2009 Apr;119(4):997-1007. doi: 10.1172/JCI38052. Epub 2009 Mar 16.

45.

Regulatory T cells differentially modulate the maturation and apoptosis of human CD8+ T-cell subsets.

Nikolova M, Lelievre JD, Carriere M, Bensussan A, Lévy Y.

Blood. 2009 May 7;113(19):4556-65. doi: 10.1182/blood-2008-04-151407. Epub 2009 Feb 25.

46.

Primary vasculitis of the central nervous system in patients infected with HIV-1 in the HAART era.

Melica G, Brugieres P, Lascaux AS, Levy Y, Lelièvre JD.

J Med Virol. 2009 Apr;81(4):578-81. doi: 10.1002/jmv.21462.

PMID:
19235861
47.

Genomewide association study of an AIDS-nonprogression cohort emphasizes the role played by HLA genes (ANRS Genomewide Association Study 02).

Limou S, Le Clerc S, Coulonges C, Carpentier W, Dina C, Delaneau O, Labib T, Taing L, Sladek R, Deveau C, Ratsimandresy R, Montes M, Spadoni JL, Lelièvre JD, Lévy Y, Therwath A, Schächter F, Matsuda F, Gut I, Froguel P, Delfraissy JF, Hercberg S, Zagury JF; ANRS Genomic Group.

J Infect Dis. 2009 Feb 1;199(3):419-26. doi: 10.1086/596067.

PMID:
19115949
48.

HIV-specific regulatory T cells are associated with higher CD4 cell counts in primary infection.

Kared H, Lelièvre JD, Donkova-Petrini V, Aouba A, Melica G, Balbo M, Weiss L, Lévy Y.

AIDS. 2008 Nov 30;22(18):2451-60. doi: 10.1097/QAD.0b013e328319edc0.

49.

HIV-1 Nef protein expression in human CD34+ progenitors impairs the differentiation of an early T/NK cell precursor.

Dorival C, Brizzi F, Lelièvre JD, Sol-Foulon N, Six E, Henry A, André-Schmutz I, Cavazzana-Calvo M, Coulombel L, Estaquier J, Schwartz O, Lévy Y.

Virology. 2008 Jul 20;377(1):207-15. doi: 10.1016/j.virol.2008.04.009.

50.

Perspectives on interleukin-7 therapy in HIV infection.

Lelièvre JD, Lévy Y.

Curr Opin HIV AIDS. 2007 May;2(3):228-33. doi: 10.1097/COH.0b013e3280fb27a5.

PMID:
19372891

Supplemental Content

Loading ...
Support Center